# Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

> **NCT02812056** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Malignant Neoplasms of Digestive Organs
- Malignant Neoplasms of Female Genital Organs
- Malignant Neoplasms of Lip Oral Cavity and Pharynx
- Malignant Neoplasms of Male Genital Organs

## Interventions

- **DRUG:** Alisertib
- **DRUG:** TAK-228

## Key facts

- **NCT ID:** NCT02812056
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-09
- **Primary completion:** 2021-09
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02812056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02812056, "Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02812056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*